Purpose A series of six lung cancer cell lines of diVerent cell origin (including small cell and mesothelioma) were characterized immunohistochemically and the role of a series of protein candidates previously implicated in drug resistance were investigated. Methods These include colony-forming and cell growth assays, immunohistochemistry, siRNA knockouts, realtime PCR and western blots. Results No correlation was found with AKT, GRP78, and ERCC1 levels and cisplatin nor oxaliplatin cytotoxicity, but an association was observed with levels of the enzyme, dihydrodiol dehydrogenase (DDH); an enzyme previously implicated in the development of platinum resistance. The relationship appeared to hold true for those cell lines derived from lung epithelial primary tumors but not for the neuroendocrine/small-cell and mesothelioma cell lines. siRNA knockouts to DDH-1 and DDH-2 were prepared with the cell line exhibiting the greatest resistance to cisplatin (A549) resulting in marked decreases in the DDH isoforms as assessed by real-time PCR, western blot and enzymatic activity. The DDH-1 knockout was far more sensitive to cisplatin than the DDH-2 knockout. Conclusion Thus, sensitivity to cisplatin appeared to be associated with DDH levels in epithelial lung cancer cell lines with the DDH-1 isoform producing the greatest eVect. Results in keeping with transfection experiments with ovarian and other cell lines.
Introduction
Cisplatin is eVective against a wide range of solid organ cancers; curative for most kinds of testicular cancer [1] and has been used in the treatment of ovarian, breast, cervical, head and neck cancer [2] . Its mode of action has been postulated to be its reactivity with the N7 position of guanine in the DNA chain (this leads to the formation of intra and interstrand cross-links [3] . The presence of intrinsic and the development of acquired tumor cell resistance subsequent to chemotherapy limit its eYcacy [4] .
Many laboratories have attempted to decipher the mechanisms of cisplatin resistance by using a human ovarian carcinoma cell line which shows between a 9-and 15-fold stable resistance to cisplatin (2008/C13). There are many biochemical alterations described in the 2008/C13 cells that are potentially associated with cisplatin resistance; they include decreased intracellular accumulation of cisplatin [5] , increased replicative bypass of cisplatin DNA adducts [6] , reduced expression of membrane-associated beta tubulin [7] and decreased expression of the intermediate Wlament cytokeratin-18 [8] . Electron microscopy shows that the resistant cells have an altered morphology and hypersensitive to lipophilic cations as opposed to the parental cells [9] . Protein kinase C and the cyclic AMP signal transduction pathways are also perturbed [10, 11] as is expression of the oncogene (c-fos); an eVect which can be partially reversed by treatment with an antisense oligonucleotide [12] . In addition, another enzyme (GST ) that has been implicated in cisplatin resistance is not altered in these cells [13] and the drug transport pump MRP-1, which has also been implicated in cisplatin resistance in other cells [14] , is not aVected [15] . Thus, there are multiple mechanisms interconnected in a complex manner responsible for cisplatin resistance in the 2008/C13 cell line.
Utilization of cDNA microarrays followed by cDNA transfection showed that an enzyme (dihydrodiol dehydrogenase) involved in the metabolic reduction and activation/ inactivation of several xenobiotics is implicated in the development of cisplatin resistance in the 2008/C13 cells [16] . DDH belongs to a superfamily of monomeric cytosolic NADP(H)-dependant oxireductases that catalyze the metabolic reduction or oxidation of several xenobiotics [17] [18] [19] . In fact, increased expression of carbonyl reductase has been demonstrated in a doxorubicin-resistant tumor cell line to produce resistance [20] and increased expression of DDH has been described in an ethacrynic acid-resistant colon carcinoma cell line [21] . These drugs, however, require metabolic conversion to an active moiety (doxorubicin) or inactivated form (ethacrynic acid) and the metabolic inactivation of cisplatin by DDH has not been described. At least four isoforms of DDH have been identiWed and characterized (DDH-1, DDH-2, DDH-3 and DDH-4; AKR1C1-4).
Recently, increased expression of DDH has been found to be a poor prognostic factor in patients with non-smallcell lung cancer [22] . These results led to the present study where a series of lung cancer cell lines (six diVerent cell types) were investigated with respect to cisplatin cytotoxicity and its potential association with the expression of a series of candidate protein targets. In addition, their sensitivity to oxaliplatin, a platinum drug active in GI cancer [23] but which is thought to produce resistance by a diVerent mechanism [24] was also investigated.
Materials and methods

Cell culture reagents, cell lines and drugs
Cell culture reagents and Gentamicin were obtained from Cellgro (Herndon, VA), RNAzol B from Tel-Test Inc. (Friendswood, TX). The lung cancer cell lines including A549, H520, H460, H23, DMS114 and H226 (Table 1) were obtained from ATCC and grown in Ham F-12 medium (A549) and RPMI-1640 medium supplemented with 10% fetal bovine serum and gentamicin at a Wnal concentration of 10 g/ml. The drugs employed included cisplatin from Aldrich Chemical Co. (Milwaukee, WI) and oxaliplatin from Alexis Biochemicals (Plymouth Meeting, PA).
Immunohistochemistry
The cells in logarithmic growth phase were centrifuged in a cytofuge, Wxed in 90% cold ethanol for 10 min at RT then reacted with the following monoclonal antibodies; AE1/AE3, Calretinin, CD56, Synaptophysin (Zymed, San Francisco, CA), Cam 5.2 (Becton-Dickinson, San Jose, CA), CK7, TTF-1, CD45, Ber-ep4, Sialosyn.TN (Dako, Carpenteria, CA), CK5/6 (Cell Marque, Rocklin, CA) and ERCC1 (Neomarkers, Fremont, CA). Detection was performed with biotin-labeled horseradish peroxidase (Ventana, Phoenix, AZ) and the staining performed using a Ventana Benchmark XT machine. The slides were scored on a 0/4+ scale by two pathologists.
MTT assays
Cells (4 £ 10 3 ) at 70% conXuency were trypsinized and seeded into 96-well plates in triplicate with 0, 0.5, 1, 5, 10, Colony-forming assays Cells (1 £ 10 5 ) were seeded in six-well plates and incubated for 24 h. They were then treated with diVerent concentrations of cisplatin (0-20 M) for 4 h. At the end of the treatment period, the cells were washed twice with drugfree medium and then trypsinized with 0.25% trypsin-0.2% EDTA to obtain single-cell suspensions. Then, 200 cells (from untreated and each treatment group) were seeded in 60 mm dishes in duplicate, followed by 2-week incubation in drug-free complete medium to allow colony growth. At the end of incubation period, culture medium was aspirated and cells were Wxed and stained with 0.5% methylene blue in 50% ethanol for 40 min at room temperature. Thereafter, the plates were gently washed with water and allowed to air-dry. Visible colonies (containing 50 or more cells each) were counted to determine the percent colony formation for each drug treatment and IC 50 values. Values were expressed as the mean § SD (standard deviation) from triplicate experiments.
Western blotting analysis
Cells, at a density of 1 £ 10 6 ml, were incubated under normal growth conditions and then washed with chilled PBS (3£) and a whole cell lysate prepared from each of the cell lines by scraping the cells into a buVer containing 20 mM Tris-HC1 pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 0.5% (v/v) Nonidet P40, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 50 mM sodium Xuoride and 1£ protease inhibitor cocktail, and incubated on ice for 30 min. The lysate was then centrifuged at 13,000g for 10 min and the supernatant was transferred to a fresh tube and stored at ¡80°C. Proteins were separated by SDS-PAGE and were transferred to a PVDF membrane. The diVerent antibodies were applied at concentrations deWned by the manufacturer to the PVDF membrane and the bands identiWed with enhanced chemiluminescence reagents (Pierce Biochemicals, Rockford, IL).
Antibodies utilized in the western blots were rabbit polyclonal HO-2 (1:2000) (BD Bioscience, San Diego, CA), rabbit polyclonal HO-1 (1:1000) (Thermo Fisher ScientiWc, Rockford, IL), rabbit polyclonal AKT (1:1000) (Cell Signaling Technology, Danvers, MA), goat polyclonal GRP78 (1:200) (Santa Cruz Biotechnology, Santa Cruz, CA), mouse polyclonal antibody to DDH-1 (1:250) and DDH-2 (1:250) (Abnova Corp., Walnut, CA), and a mouse monoclonal antibody against DDH-3 (1:2000) (Abcam, Cambridge, MA). The secondary antibodies were goat anti-rabbit and rabbit (1:4000) anti-goat (Pierce, Rockford, IL) and rabbit anti-mouse (Thermo Fisher ScientiWc, Rockford, IL).
DDH knockdown in A549 cells
siRNAs corresponding to DDH-1 and DDH-2 genes were designed according to pSilencer neo instruction manual (Ambion, USA). BrieXy, the 21-nt potential sequences in the target mRNAs of DDH that begin with an AA dinucleotide were found and compared to the human genome database using BLAST (http://www.ncbi.nlm.nih.gov/BLAST). Any target sequences with more than 16-17 contiguous base pairs of homology to other coding sequences were eliminated from consideration. The hairpin siRNA template oligonucleotides were designed by a web-based insert design tool. For each gene, three pairs of sequences were designed and the following gene-speciWc sequences were selected as optimal: DDH-1: sense sequence: 5Ј-GCCCAU UGGCCAGAAAAAATT-3Ј, antisense sequence: 5Ј-UUU UUUCUGGCCAAUGGGCTT-3Ј; DDH-2 sequence: 5Ј-G CUACAGCUAAGCCCAUCGTT-3Ј, antisense sequence: 5Ј-CGAUGGGCUAGCUGUAGCTT-3Ј. The siRNAsassociated DNA sequences were synthesized and inserted into the BamH1 and HindIII sites of a pSilencer 3.1 neo vector (Ambion, Austin, TX) and referred to as pSilencer-DDH-1 or DDH-2. All siRNA-associated plasmids were analyzed by restriction endonuclease digestion and DNA sequencing before use. Negative control, siRNA (Cat. #4611, lot #074 P24A) and GFP control insert p-Silencer (lot #033P00B) were obtained from Ambion (Austin, TX). Human lung cancer A549 cells were prepared in six-well plates at a density of 2 £ 10 5 cells per well, grown for 24 h and then transfected with 1 g of siRNA plasmid (pSilencer 3.1-DDH-1 or DDH-2) using lipofectamine 2000 (Invitrogen, Carlsbad, CA) in serum-free Ham's F-12 medium as described by the manufacturer's protocol. BrieXy, 2 l of lipofectamine 2000 was added to 100 l Ham's F-12 serum-free medium which was kept at room temperature for 10 min. One microgram of siRNA plasmid were added to 100 l Ham's F-12 and the diluted lipofectamine 2000 was added to the diluted siRNAs and siRNA plasmids and incubated for 20 min at room temperature. The pre-incubated cells were washed with serum-free medium and 0.8 ml medium and 0.2 ml of the transfection mixture added to each well. After a 5-h incubation, the transfected cells were trypsinized and diluted to grow in medium with G418 at a Wnal concentration of 700 g/ml. Negative siRNA sequences and empty pSilence 3.1 vector were used as controls. The clones were maintained in RPMI-1640 medium supplemented with G418 (700 g/ml) (Ambion, Austin, TX).
Semi quantitative RT-PCR analysis
Total RNA was isolated from the cells after a brief wash (2£) with cold PBS (pH 7.4), RNAzol (Tel-test, Friendswood, TX), was added followed by chloroform extraction, isopropanol precipitation, and a 75% (v/v) ethanol-DEPC wash. The reverse transcription reaction consisted of 1 g of RNA, 4 units of Omniscript RT, 1 M oligo-dT primer, 0.5 mM dNTP, 10 units of RNase inhibitor, and 1£ RT buVer. Reverse transcription was performed at 37°C for 1 h and inactivated at 93°C for 3 min. The cDNA was then ampliWed by PCR using gene-speciWc primer pairs. Each PCR consisted of 1£ PCR buVer, 1.5 mM MgCl 2 , 200 M dNTP, 2.5 units of Taq Polymerase and 0.2 mM gene-speciWc forward (F) and reverse (R) primers. The PCR conditions were as follows: an initial denaturation at 94°C for 15 s, 55°C for 30 s, 72°C for 30 s for the number of cycles optimized for each primer to ensure that the product intensity fell within the linear phase of ampliWcation, and then a Wnal elongation step was performed for 10 min at 72°C. RT-PCR ampliWcation of GAPDH transcript was used as the internal control to verify that equal amounts of RNA were used from each cell line. The PCR products were separated on a 1.5% agarose gel stained with ethidium bromide (0.35 g/ml) by electrophoresis in 1£ Tris borate EDTA buVer. A HaeIII digest of A-X174 DNA was used as a standard marker.
Real-time (RT) PCR analysis
For the real-time PCR analysis, SYBR green dye was utilized in each of the PCRs using an Eppendorf Realplex PCR System. The reaction mixture included 1 g of RNA, 4 units of omniscript RT, 1 M of oligo (dT) primer, 0.5 mM dNTP, 10 units of RNAase inhibitor and 1£ RT buVer and was performed at 37°C for 1 h followed by incubation at 93°C for 3 min. Thereafter, an equal volume of cDNA was ampliWed using the gene-speciWc primer pairs in a reaction mixture consisting of 1£ PCR buVer, 1.5 mM MgC1 2 , 200 M dNTP, 2.5 units of Taq polymerase and 0.2 mM of gene-speciWc forward and reverse primers. The initial denaturation was 94°C for 3 min was followed by 94°C for 15 s, 55°C for 30 s, then 72°C for 30 s for a number of cycles optimized for each primer. The Wnal elongation step was performed for 10 min at 72°. The cycle threshold values were collected and analyzed by the Mastercycler Eppendorf Realplex software system. The primers were designed using a software program: Primer Express, Version 1 from Applied Biosystems (Foster City, CA).
For absolute quantiWcation of DDH-1 and DDH-2 mRNA levels, a standard curve was generated utilizing 30-300,000 copies of linearized plasmids containing DDH-1 or DDH-2 full-length cDNA as templates. The plasmids containing the full-length DDH-1 and DDH-2 cDNA have been described before [35] . Absolute quantiWcation of DDH-1 and DDH-2 mRNA was achieved by the regression equations obtained from the standard curves as described (http://docs.appliedbiosystems.com/pebiodocs/04371090. pdf, Applied Biosystems).
DDH enzyme activity
Cells were plated at a density of 2 £ 10 6 in 100-mm plates and incubated for 24 h. At the end of the incubation period, the cells were washed with chilled, phosphate-buVered saline, and scraped into a buVer containing 10 mM sodium phosphate (pH 7.4), 150 mM KCl and 0.5 mM EDTA (BuVer A). After a brief centrifugation, the cells were resuspended in BuVer A containing protease inhibitor cocktail and homogenized in a glass Dounce homogenizer with a tight Wtting pestle. The lysed homogenate was centrifuged at 14,000g for 20 min. The supernatant fraction was further centrifuged at 100,000g for 60 min to separate the cytosol fraction. Aliquots were stored at ¡70°C until use. The protein concentration was determined by the Coomassie blue assay (Bio-Rad, Hercules, CA) using BSA as a standard. Enzyme activity was then assayed in a reaction mixture consisting of 4 mM NADP+, 0.1 mM potassium phosphate, pH 7.0, with indicated concentrations of substrate and the cytosolic fraction. The reaction was started by addition of
substrate, and the disappearance of NADPH at 25°C was monitored with the aid of a Beckman DU-70 recording spectrophotometer at 340 nm. An assay mixture containing all of the components except the substrate served as the blank. Initial rates of NADPH disappearance were determined in triplicate.
Statistical analysis
The linear regression analysis for IC 50 values and paired t test were performed using Excel and the SigmaStat Statistical Analysis System, Version 1.01. P values were considered to be signiWcant when P < 0.05.
Results
Characterization of the cell lines
The cells were characterized by immunohistochemistry (Table 1 ) and it is apparent that A549, H460 and H23 are all epithelial non-small carcinomas of the lung as evidenced by expression of keratins and non-expression of markers of squamoid diVerentiation such as CK5/6. A549 appears to be an adenocarcinoma whereas H520 shows squamoid diVerentiation (CK5/6 positive) correlating to the ATCC designation of the original cell lines. H460 and H23 are best classiWed as poorly diVerentiated non-small-cell lung carcinomas. Immunohistochemical staining of the DMS114 cells with synaptophysin and CD56 show this line to be of small-cell/neuroendocrine origin. Positive staining of the H226 cells by calretinin and their negativity to Ber-EP4 (positive if an adenocarcinoma) and sialosyl-Tn show that this cell line is of mesothelial cell origin (ATCC designation: squamoid/mesothelioma). Thus, the modern immunohistochemical staining analysis correlates quite well with the origin of cell lines listed by the ATCC-derived from the primary tumors 20 years ago when modern immunotyping was not available. TTF staining is negative; a not unexpected Wnding since these cells are morphologically undiVerentiated (high proliferation rate) and although this marker is positive in 72% of lung adenocarcinomas only 5% of squamous and 0% in large cell are positive; additionally, this marker is not positive in tumors with a high proliferation index [25] . (See Table 1 for Ki67 proliferation index.)
Cytotoxicity assays
It can be seen when colony-forming assays are performed with these cells lines that the IC 50 to cisplatin of the nonsmall-cell epithelial cell lines decreases with A549 > H520 = H460 > H23 (Table 2) and that the IC 50 values are high (except H23) relative to human ovarian cells sensitive to cisplatin (2008, A2780). However, the small-cell/neuroendocrine cell line (DMS114) and the mesothelial cell line (H226) appear to have resistance to cisplatin (similar to H520 and H460). If oxaliplatin is compared to cisplatin, some correlation is observed with the epithelial cells with A549, H520 and H460 being equally resistant and H23 still the most sensitive but the mesothelial cell line H226 appears sensitive to oxaliplatin.
Western blots
Various proteins have been implicated in drug resistance in lung cancer cell lines including those involved in the AKT pathway [26] , ROS generation (HO-1 and HO-2) [27, 28] , 14-3-3zeta [29] pathway and the ER stress pathway (GRP78) [30] . mRNA and protein expression were investigated-no association with cisplatin resistance was observed between the levels of HO-1, 14-3-3zeta or GRP78 ( Fig. 1 ) with minimal changes observed between the cell lines; AKT levels showed poor correlation with very high levels in H460 and 226 and high levels of HO-1 were only observed in DMS114 and minimal levels in H520. However, when DDH-1, DDH-2 and DDH-3 were analyzed, the NSCL cell lines (A549, H520, H460 and H23) showed an association with decreased expression of total DDH (and to a lesser extent DDH-1) with decreased resistance to cisplatin (Fig. 2) . The non-epithelial cell lines (DMS114 and H226) showed little correlation with cisplatin cytotoxicity with low levels of DDH but relatively high resistance to the drug. Immunologic staining for ERCC1, a DNA excision repair enzyme that has been implicated in cisplatin resistance [31] showed staining that was primarily cytoplasmic with little nuclear positivity (the control tissue showed (Table 1) . A recent investigation reported only half of lung tumors showed nuclear positivity for this enzyme [32] .
DDH knockdown in A549 cells
In order to investigate the possible role of DDH in producing cisplatin resistance, siRNA transfectants of DDH-1, DDH-2 and DDH-3 were cloned into the most highly resistant cell line (A549), which was deWned as an adenocarcinoma/non-small-cell carcinoma of the lung. siRNA transfection of DDH-3 could not be performed in this and other human ovarian cell lines since the transfected cells died; a result which was not unexpected since DDH-3 has recently been implicated in controlling cell growth [33] .
The DDH-1 (A8n3) and DDH-2 (A7n1) siRNA transfectants showed decreased levels of DDH-1 and 2 RNA as assessed by RT-PCR (Fig. 3a) , and real-time PCR (Table 3A) . Western blots showed that the DDH-1 knockdown A8n3 showed a marked decrease in both total DDH and DDH-1 (Fig. 3b, c) ; the DDH-2 knockdown (A7nl) showed a much smaller decrease in both total DDH and DDH-1 and these results correlated with the decreased in enzymatic activity (Table 3B ). The decrease in DDH-1 in the DDH-2 knockdown was due probably to the 98% homology between the two isoform gene sequences. Colony-forming and MTT assays performed with these transfectants show a marked aVect on the IC 50 to cisplatin produced by the introduction of the DDH-1 siRNA (A8n3) vector and a far lesser aVect with the DDH-2 transfectant (A7n1) ( Table 4 ). This paralleled the marked eVect DDH-1 produced when human ovarian (2008) and lung (calu) cell lines were transfected with DDH-1 and DDH2 [34] , but not the recent results of Hung et al. [40] , who showed the reverse with H23 lung cells. Interestingly, the IC 50 (CFA) of the DDH-1 knockout (A8n3) is higher than H23 but H23 has less DDH-3 than A8n3 suggesting that perhaps this isoform, as well as DDH-1, may play a role in cisplatin resistance as has been reported with the 2008 human ovarian carcinoma cell [35] .
Discussion
An investigation was initiated to study the role of various proteins involved in widely diVerent cellular pathways. Some of these proteins have been implicated in the development of cisplatin resistance in lung cancer and include AKT [27] . HO-1, a protein induced by stress-stimulation including chemopreventive agents [28] and HO-2 its partner, which has been implicated in cisplatin resistance in human ovarian 2008 cells [35] . The up-regulation of 14-3-3zeta, which can result in down-regulation of the AKT/PI-3 kinase pathway, was investigated since increased expression correlated to poor outcome in NSLC lung cancer and its down-regulation in lung cancer A549 cells sensitizes these cells to cisplatin [29] . GRP78 is an endoplasmic Fig. 1 Protein expression of AKT, HO-1, HO-2, 14-3-3zeta and GRP78 in six lung cancer cell lines; Lane 1 (A549), 2 (H460), 3 (H520), 4 (H23), 5 (H226) and 6 (DMS114), as analyzed by western blot analysis. The protein extraction and separation was performed as described in the "Materials and methods" section. Actin was used as an internal control to ensure equal loading of each lane reticulum stress protein which has been implicated in predicting chemotherapeutic response in breast [36] , prostate [37] and lung [20] cancer; with higher levels generally correlating to poor outcome. ERCC1, a member of the excision repair cross-complementary group-1 proteins, has also been implicated in the development of cisplatin resistance in lung cancer with positivity correlating to poor survival and cisplatin resistance [32] . All six proteins from these widely diVerent pathways appeared to correlate poorly with cisplatin cytotoxicity in the six lung cancer cell lines studied, four of epithelial, one of neuroendocrine and one of mesothelial origin. Recently, work with a human ovarian cancer cell line which exhibits stable resistance to cisplatin implicated an enzyme, dihydrodiol dehydrogenase, in the production of resistance to cisplatin and carboplatin in a wide range of cells derived from cancers from diVerent primary sites [34] . This enzyme, a member of the superfamily of monomeric cytosolic NADPH-dependent oxireductases, catalyzes the interconversion of aldehydes and ketones to alcohols. Involvement of oxireductases in producing drug resistance has been reported, albeit in a few cases; in human colon cancer cells with ethacrylic acid [20] and in a doxorubicinresistant cell line [21] . When DDH isoforms were transfected into a wide range of tumor cell types, ubiquitous induction of cisplatin resistance and carboplatin resistance was observed primarily with DDH-1 and to a far lesser extent with DDH-2 and DDH-3 [34] . The transfected cells showed no cross-resistance to other widely used chemotherapeutic agents including taxol, vincristine, doxorubicin and melphalan, except in the case of a germ cell tumor cell line (Tera) that was found to be cross-resistant to vincristine and doxorubicin. However, in this study, human lung cancer cell lines from disparate origins were studied and cisplatin sensitivity appears only to be associated with DDH-1, DDH-2 or DDH-3 expression in the four epithelial cell carcinomas but not in a neuroendocrine/small-cell or mesothelioma-derived cell line. These results have been substantiated here by RNA interference experiments with DDH-1 and DDH-2 which showed that decreasing DDH-1 in the most highly resistant cell line (A549) produced marked decreases in the IC 50 to cisplatin. Interestingly, resistance to oxaliplatin appears markedly decreased when compared to cisplatin with the mesothelial cell line (H226); a not unexpected result since the latter drug has been shown to have a diVerent mode of action to that of cisplatin producing primarily DNA-strand breaks as opposed to cross-links [23] . In addition, studies on the development of resistance to oxaliplatin shows (although the studies are meager) show that an altered mode of drug uptake may explain the development of resistance in a human ovarian as well as a colon cancer cell line [24] . Both sets of results may explain why oxaliplatin is useful in treating GI and colon cancers whereas cisplatin is relatively ineVective [38] .
How DDH exerts its eVect is still a matter of speculation; there are no studies as yet showing any direct interaction with cisplatin. Studies have implicated ROS in certain human ovarian cell lines but no correlation with basal ROS levels was observed with these lung cell lines.
Studies are currently underway to determine whether the expression of DDH has a clinical role in lung cancer.
A preliminary study suggested that it may play an important role in predicting outcome and prognosis in lung cancer has appeared but whether the patients with poor prognoses were due to treatment failure with cisplatin was not addressed [22] . In addition, identiWcation of which DDH isoforms were implicated was not investigated in the clinical material although DDH transfection into an epithelial lung cell line (H-23) showed resistance with both DDH-1 and DDH-2 transfectants [39] with the latter producing the greatest eVect. Results contrary to reports with both lung and ovarian cells where DDH-1 transfection produced a far greater eVect than DDH-2 [34] and the experiments described here where DDH-1 knockdown decreased cisplatin cytotoxicity far more than DDH-2. The primer described by Hung et al. [39] is not speciWc and will produce both DDH-1 and DDH-2 isoforms and a polyclonal antibody was employed (not speciWc for either isoform), and this may explain the discrepant results. 
